Issues in the management of Alzheimer's disease

Martin Farlow, Fraser Inglis

Research output: Contribution to journalReview article

Abstract

The cholinesterase inhibitors are widely accepted as being the gold standard treatment for mild-to-moderate AD. Recent data support the early initiation and continued use of these agents over the long term. However, the current average duration of treatment is less than one year, possibly due to disappointing efficacy of the initial treatment. In such cases, pharmacological differences between available cholinesterase inhibitors provide a good rationale to switch to another drug in the same class. For example, evidence from two prospective studies has shown that about 50% of patients failing to benefit from donepezil treatment experienced significant improvements after being switched to rivastjgmine. Pharmacological differences between available cholinesterase inhibitors may determine differences in their clinical profiles, and switching strategies may be employed to provide optimal, long-term benefits.

Original languageEnglish (US)
Pages (from-to)107-108
Number of pages2
JournalPrimary Care Psychiatry
Volume8
Issue number3
DOIs
StatePublished - Sep 1 2002

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Pharmacology
Therapeutics
Prospective Studies
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Clinical practice
  • Donepezil
  • Rivastigmine
  • Switching strategies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Issues in the management of Alzheimer's disease. / Farlow, Martin; Inglis, Fraser.

In: Primary Care Psychiatry, Vol. 8, No. 3, 01.09.2002, p. 107-108.

Research output: Contribution to journalReview article

Farlow, Martin ; Inglis, Fraser. / Issues in the management of Alzheimer's disease. In: Primary Care Psychiatry. 2002 ; Vol. 8, No. 3. pp. 107-108.
@article{9704d4186243475ea6862398607548e7,
title = "Issues in the management of Alzheimer's disease",
abstract = "The cholinesterase inhibitors are widely accepted as being the gold standard treatment for mild-to-moderate AD. Recent data support the early initiation and continued use of these agents over the long term. However, the current average duration of treatment is less than one year, possibly due to disappointing efficacy of the initial treatment. In such cases, pharmacological differences between available cholinesterase inhibitors provide a good rationale to switch to another drug in the same class. For example, evidence from two prospective studies has shown that about 50{\%} of patients failing to benefit from donepezil treatment experienced significant improvements after being switched to rivastjgmine. Pharmacological differences between available cholinesterase inhibitors may determine differences in their clinical profiles, and switching strategies may be employed to provide optimal, long-term benefits.",
keywords = "Alzheimer's disease, Cholinesterase inhibitors, Clinical practice, Donepezil, Rivastigmine, Switching strategies",
author = "Martin Farlow and Fraser Inglis",
year = "2002",
month = "9",
day = "1",
doi = "10.1185/135525703125001596",
language = "English (US)",
volume = "8",
pages = "107--108",
journal = "Primary Care Psychiatry",
issn = "1355-2570",
publisher = "Librapharm",
number = "3",

}

TY - JOUR

T1 - Issues in the management of Alzheimer's disease

AU - Farlow, Martin

AU - Inglis, Fraser

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The cholinesterase inhibitors are widely accepted as being the gold standard treatment for mild-to-moderate AD. Recent data support the early initiation and continued use of these agents over the long term. However, the current average duration of treatment is less than one year, possibly due to disappointing efficacy of the initial treatment. In such cases, pharmacological differences between available cholinesterase inhibitors provide a good rationale to switch to another drug in the same class. For example, evidence from two prospective studies has shown that about 50% of patients failing to benefit from donepezil treatment experienced significant improvements after being switched to rivastjgmine. Pharmacological differences between available cholinesterase inhibitors may determine differences in their clinical profiles, and switching strategies may be employed to provide optimal, long-term benefits.

AB - The cholinesterase inhibitors are widely accepted as being the gold standard treatment for mild-to-moderate AD. Recent data support the early initiation and continued use of these agents over the long term. However, the current average duration of treatment is less than one year, possibly due to disappointing efficacy of the initial treatment. In such cases, pharmacological differences between available cholinesterase inhibitors provide a good rationale to switch to another drug in the same class. For example, evidence from two prospective studies has shown that about 50% of patients failing to benefit from donepezil treatment experienced significant improvements after being switched to rivastjgmine. Pharmacological differences between available cholinesterase inhibitors may determine differences in their clinical profiles, and switching strategies may be employed to provide optimal, long-term benefits.

KW - Alzheimer's disease

KW - Cholinesterase inhibitors

KW - Clinical practice

KW - Donepezil

KW - Rivastigmine

KW - Switching strategies

UR - http://www.scopus.com/inward/record.url?scp=0038555477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038555477&partnerID=8YFLogxK

U2 - 10.1185/135525703125001596

DO - 10.1185/135525703125001596

M3 - Review article

AN - SCOPUS:0038555477

VL - 8

SP - 107

EP - 108

JO - Primary Care Psychiatry

JF - Primary Care Psychiatry

SN - 1355-2570

IS - 3

ER -